By admin 
Including the Cancer Research Institute (CRI) in one’s will represents a profound personal commitment to fostering a future where cancer is no longer a life-threatening disease, but a condition the human body is equipped to overcome. This act of philanthropic foresight is not merely a donation; it is a legacy investment in groundbreaking science, driven by a myriad of motivations from individuals across the globe. Many supporters are moved by the direct impact of lifesaving immunotherapy treatments on themselves or their loved ones, witnessing firsthand the revolutionary potential of harnessing the body’s own defenses against cancer. Others are drawn to CRI’s established reputation as a pioneering force, consistently pushing the boundaries of scientific advancement in the field since its inception. Regardless of the specific impetus, all who choose to make a gift to CRI through their estate understand the critical, far-reaching importance of this work.
The Cancer Research Institute offers various distinct avenues for individuals to contribute generously and thereby accelerate progress in immunotherapy. Among the most impactful, yet often overlooked, is the legacy gift, a simple and flexible option for long-term support. With August officially recognized as "Make-A-Will Month," the present moment offers a unique and timely opportunity for individuals to formalize their estate plans, ensuring their philanthropic intentions are clearly articulated and effectively realized. This designated month serves as a crucial reminder for everyone to engage in thoughtful estate planning, a process that extends beyond financial arrangements to encompass personal values and the causes one wishes to support posthumously.
The Enduring Impact of Legacy Giving in Medical Research
Legacy gifts, also known as planned gifts or bequests, form the bedrock of long-term funding for many non-profit organizations, particularly those engaged in complex, multi-year scientific research. Unlike immediate cash donations, bequests provide a stable, predictable stream of revenue that allows institutions like CRI to plan for ambitious, sustained research initiatives that often span decades. This foresight is crucial in fields like cancer immunotherapy, where discoveries can take years to translate from laboratory benches to patient bedsides. Donors often appreciate that a legacy gift allows them to make a substantial contribution that might not be feasible during their lifetime, extending their philanthropic reach far into the future. The act of including a charity in a will is a testament to an individual’s deep-seated belief in a cause, a final, powerful statement of their commitment to creating a better world.
CRI’s Unwavering Commitment to Governance and Fiscal Responsibility
A significant factor underpinning donor confidence in CRI is its consistent recognition from independent third-party assessors for exemplary governance and stringent fiscal responsibility. As Katherine Pooser, Director of Planned Giving at CRI, emphasized, "When a person generously gives through a will or living trust, they can do so with confidence knowing CRI regularly receives recognition from third-party assessors for its good governance and fiscal responsibility." This assurance is paramount for donors who wish to ensure their contributions are maximized for impact. Organizations like Charity Navigator, an independent charity evaluator, consistently award CRI high ratings – often a perfect four-star score – signifying exceptional financial health, accountability, and transparency. This means that a very high percentage of every dollar donated directly supports programs and research, rather than administrative overhead. Such endorsements are not merely symbolic; they are objective validations that CRI operates with integrity, efficiency, and a clear focus on its mission. Pooser further highlighted the tangible impact of these gifts, stating, "Supporters can also be confident that their gift makes a real difference. Bequests of every size come together to make up a substantial part of the funding that drives the next wave of immunotherapy developments." This collective power of individual legacy gifts underscores their indispensable role in advancing a complex and costly field of science.
Fueling the Next Wave of Immunotherapy Developments: A Historical Perspective
The concept of immunotherapy, harnessing the body’s own immune system to fight disease, has a fascinating and extensive history, though its modern resurgence as a mainstream cancer treatment is relatively recent. Early pioneers like Dr. William Coley in the late 19th century observed that some cancer patients experienced remission after bacterial infections, leading him to develop "Coley’s Toxins" – a rudimentary form of immunotherapy. While his methods were controversial and lacked the scientific rigor of today, they laid foundational ideas. The true revolution, however, gained significant momentum in the late 20th and early 21st centuries, propelled by decades of basic research into immunology.
CRI was founded in 1953 by Helen Coley Nauts, William Coley’s daughter, with the explicit mission to continue her father’s work and to support fundamental research into cancer immunology. For decades, CRI was a lone voice advocating for the immune system’s potential in cancer therapy, often against prevailing scientific skepticism that focused primarily on chemotherapy and radiation. This unwavering commitment proved prescient. Key breakthroughs, such as the discovery of immune checkpoints (like CTLA-4 and PD-1/PD-L1) by scientists like James P. Allison and Tasuku Honjo (who later shared the Nobel Prize in Physiology or Medicine in 2018 for their work), transformed the field. These discoveries led to the development of "checkpoint inhibitors," drugs that release the brakes on the immune system, allowing it to recognize and attack cancer cells more effectively.
Legacy gifts are critical because they enable CRI-funded scientists to pursue this rigorous immunotherapy research, which promises to benefit countless cancer patients worldwide. Immunotherapy is not a one-size-fits-all solution; it encompasses a broad spectrum of approaches including checkpoint inhibitors, CAR T-cell therapy, oncolytic viruses, therapeutic cancer vaccines, and more. Each of these modalities requires intensive, long-term research to optimize efficacy, understand resistance mechanisms, and expand applicability to more cancer types. The financial support derived from bequests provides the stability necessary for scientists to embark on such ambitious projects, free from the immediate pressures of short-term grant cycles. This allows for more speculative, high-reward investigations that often lead to paradigm-shifting discoveries.
Spotlight on Groundbreaking Research and Collaborative Networks
CRI’s funding directly empowers some of the brightest minds in immunology and oncology. For instance, research conducted by CRI-funded scientists delves into highly specialized areas, such as Dr. Tamar Lea Ben-Shaanan’s exploration of the intricate relationship between sensory neurons and lung cancer. Her work aims to uncover novel pathways through which the nervous system might influence tumor growth and immune responses, potentially leading to entirely new therapeutic targets. Similarly, Dr. Peng Jiang’s research harnesses the power of artificial intelligence (AI) to help scientists analyze complex datasets related to T cells, the immune system’s primary cancer-fighting agents. By leveraging AI, researchers can identify subtle patterns and biomarkers that predict patient response to immunotherapy, personalize treatment strategies, and accelerate drug discovery. These are just two examples of the diverse and cutting-edge projects that rely on sustained funding.
The impact of CRI extends beyond individual grants, fostering a vibrant, collaborative network of researchers. Dr. Lloyd Bod, PhD, a CRI Thompson Family Foundation CLIP Investigator and Assistant Professor of Medicine at Massachusetts General Hospital, eloquently articulates this benefit: "Being a CRI CLIP Investigator is an honor, and not only provides crucial funding, but also also connects me with a network of researchers dedicated to making groundbreaking discoveries in immunotherapy." The Cancer Research Institute’s Clinic and Laboratory Integration Program (CLIP) specifically supports scientists who are working to bridge the gap between basic laboratory research and clinical application, ensuring that scientific discoveries are translated into tangible patient benefits as rapidly as possible. Dr. Bod further emphasizes, "It is a commitment to pursuing innovative science that can lead to life-saving therapies for patients worldwide." This emphasis on collaboration, mentorship, and translational research amplifies the impact of every donated dollar, creating a synergy that accelerates progress across the entire field.
Broader Implications: Philanthropy’s Role in Medical Advancement
The role of private philanthropy in advancing medical science, particularly in high-risk, high-reward areas like immunotherapy, cannot be overstated. While government funding bodies like the National Institutes of Health (NIH) provide substantial support, they often prioritize established research areas or those with immediate clinical applicability. Philanthropic organizations like CRI, fueled significantly by legacy gifts, have the flexibility to fund more exploratory, fundamental research that may not yield immediate results but is essential for future breakthroughs. This "venture philanthropy" model allows scientists to pursue innovative ideas that might be deemed too risky for traditional funding mechanisms, yet hold the potential for truly transformative discoveries.
The stability provided by bequests allows CRI to commit to multi-year funding cycles, giving scientists the freedom to pursue complex questions without constant pressure to secure new grants. This long-term view is critical for nurturing scientific talent, building specialized laboratories, and developing robust research programs that can attract and retain leading experts. In an era where cancer remains a leading cause of death globally – with an estimated 1.9 million new cancer cases and 609,820 cancer deaths projected in the United States in 2023 alone, according to the American Cancer Society – sustained investment in innovative therapies is not just desirable, but absolutely essential. Immunotherapy has already transformed the outlook for patients with melanoma, lung cancer, kidney cancer, and various hematological malignancies, and its potential to impact many more cancer types is still being uncovered.
Navigating the Process: Practical Steps for Legacy Giving
For those considering including CRI in their estate plans, the process is designed to be straightforward and flexible. A legacy gift can take many forms, tailored to individual circumstances and preferences:
- Specific Bequest: Designating a specific dollar amount or a particular asset (e.g., real estate, stocks) to CRI.
- Residuary Bequest: Gifting a percentage or all of the remainder of one’s estate after all other debts, taxes, and specific bequests have been satisfied. This is a common and highly impactful way to give.
- Contingent Bequest: Specifying that CRI will receive a gift only if certain conditions are met (e.g., if other beneficiaries predecease the donor).
- Living Trust: Establishing a revocable or irrevocable trust that includes CRI as a beneficiary, allowing for greater control and flexibility during the donor’s lifetime.
- Beneficiary Designation: Naming CRI as a beneficiary of a retirement account (e.g., IRA, 401k), life insurance policy, or bank account. This can be a very tax-efficient way to give.
It is highly recommended that individuals consult with a qualified estate planning attorney and a financial advisor. These professionals can provide personalized guidance, ensure that the will or trust accurately reflects the donor’s wishes, and help optimize the gift for both philanthropic impact and potential tax benefits. CRI’s office of gift planning also serves as a valuable resource, ready to answer questions and provide information to facilitate this important decision.
No matter the specific details of a donor’s will or living trust, CRI expresses profound gratitude for every contribution. These gifts directly fuel the scientific research conducted by the brightest minds in immunotherapy, fostering discoveries that hold the promise of transforming cancer treatment and prevention. The Cancer Research Institute extends its sincere thanks to all who consider including the organization in their estate plans, recognizing that such foresight and generosity are pivotal in the collective endeavor to create a world immune to cancer. For any questions regarding wills and bequests, individuals are encouraged to contact CRI’s office of gift planning directly at 212-792-5212. This simple call can be the first step in leaving a powerful and enduring legacy of hope and health for generations to come.
